Processa Pharmaceuticals, Inc. — Director's Dealing 2021

Apr 15, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Processa Pharmaceuticals, Inc. (PCSA)
CIK: 0001533743
Period of Report: 2021-04-13

Reporting Person: Yorke Justin W (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-13	Common Stock	S	6500	$9.86	Disposed	257972	Indirect
2021-04-14	Common Stock	S	9700	$9.42	Disposed	248272	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	300706	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.65 to $10.15, inclusive. The Reporting Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.31 to $9.50, inclusive. The Reporting Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.